The PACIFIC study is testing how well baxdrostat with dapagliflozin work together in adults with chronic kidney disease and high blood pressure

Join now

About the study

  • Status: Enrolling now

  • Condition: Chronic Kidney Disease (CKD)

  • Study treatments: baxdrostat and dapagliflozin

Key criteria

  • Reduced kidney function

  • Taking medication to lower blood pressure- either an ACE inhibitor* or ARB*

  • Not on dialysis treatment

  • Age: 18 years and older

  • Sex: all

(*angiotensin-converting enzyme, angiotensin 2 receptor blocker)

Study details

  • Participation length: Up to 5 years

  • Number of visits: Up to 24

  • Phase: 3

  • Potential placebo: Yes

About

The PACIFIC study is for adults living with CKD who are taking medication to lower their blood pressure- either an ACE inhibitor (angiotensin-converting enzyme) or ARB (angiotensin 2 receptor blocker). The study is testing whether taking baxdrostat and dapagliflozin together can reduce the risks of kidney failure or serious heart problems better than taking dapagliflozin alone.

Study treatment description

What are baxdrostat and dapagliflozin?

Baxdrostat is a study medication that is being tested to see if it stops extra fluid and waste from building up in the body and reduces high blood pressure.

Dapagliflozin is a type of medication that is already approved to help people with CKD. It helps the body remove sugar from the blood through the urine and helps to slow the worsening of kidney function in CKD. You may already be taking dapagliflozin or another SGLT2 inhibitor* to treat your CKD.

Everyone in the study will receive dapagliflozin. Half the people in the study will take dapagliflozin with baxdrostat and the other half will receive dapagliflozin and a placebo*.

(*SGLT2 inhibitor (sodium–glucose cotransporter-2) is a type of treatment that helps the kidneys remove more salt and sugars from the body)

(*Placebo: a placebo looks like real medicine but has no active ingredients. Some trials use them for comparison, but many compare new and standard treatments.)

What does the study involve?

See below for a summary of the timing and key activities that will happen during this study.

Before

  • Up to 6 weeks

  • 1 – 3 study doctor visits

  • Decide if the study is right for you

  • Physical exams, blood, urine and heart tests

During

  • Up to 5 years

  • Receive study treatments

  • 13 - 21 study doctor visits

  • Physical exams, blood, urine and heart tests

After

  • Study doctor visit

  • Physical exams, blood, urine and heart tests

Join now
Next
Next

nefXtend study: Extension for TARPEYO® (budesonide) delayed release capsules